The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2018

Filed:

Mar. 16, 2017
Applicant:

Shaperon Inc., Seoul, KR;

Inventors:

Seung Yong Seong, Seoul, KR;

Youn Hee Kim, Seoul, KR;

Assignee:

SHAPERON Inc., Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 8/02 (2006.01); A61K 8/72 (2006.01); A61K 38/00 (2006.01); A61K 31/575 (2006.01); A61K 31/728 (2006.01); A61K 9/06 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 8/63 (2006.01); C11D 13/26 (2006.01); C11D 13/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/575 (2013.01); A61K 8/63 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/14 (2013.01); A61K 9/16 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/728 (2013.01); C11D 13/10 (2013.01); C11D 13/26 (2013.01);
Abstract

The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases.


Find Patent Forward Citations

Loading…